UCB (OTCMKTS:UCBJY) Upgraded by Zacks Research to “Hold” Rating

UCB (OTCMKTS:UCBJY) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other research firms also recently issued reports on UCBJY. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

UCB Trading Down 1.2%

OTCMKTS:UCBJY opened at $144.63 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. UCB has a 1 year low of $98.24 and a 1 year high of $168.76. The stock’s 50 day simple moving average is $143.65 and its two-hundred day simple moving average is $148.03.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.